Valneva (NASDAQ:VALN) Issues Earnings Results

Valneva (NASDAQ:VALN) posted its quarterly earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.17), Zacks reports. Valneva had a negative net margin of 110.33% and a negative return on equity of 142.99%. The firm had revenue of $39.37 million for the quarter, compared to analysts’ expectations of $43.15 million.

Here are the key takeaways from Valneva’s conference call:

• Lyme vaccine regulatory progress advanced: Pfizer has filed the candidate with the European Medicines Agency and is working with the FDA toward a planned BLA submission, with regulatory decisions expected within the next 12 months. Valneva highlighted efficacy above 70%, though the initial analysis missed the lower bound of its confidence interval.
• Valneva ended the first half with €121.5 million in cash and reaffirmed 2026 product-sales guidance of €135 million–€150 million and total-revenue guidance of €145 million–€160 million. Restructuring and cost-saving measures are expected to improve cash flow and earnings in the second half and beyond.
• First-half product sales fell to €64 million from €91 million, while total revenue declined to €65.8 million from €97.6 million. The operating loss widened to €49.9 million and adjusted EBITDA loss to €40.1 million, partly due to lower sales and one-time IXCHIQ manufacturing cancellation fees and inventory impairment.
• IXCHIQ travel-market uptake remains slow, prompting Valneva to evaluate a greater focus on endemic markets. Brazil has approved Butantan’s locally manufactured version, and a government pilot campaign has vaccinated more than 50,000 people, with a target of at least 100,000.
• Results from the shigella vaccine’s infant immunogenicity/safety study and adult human-challenge study are expected in the coming months. Valneva will use the data to determine whether to advance or optimize the program’s dose, schedule, or formulation.

Valneva Price Performance

NASDAQ:VALN opened at $7.13 on Friday. Valneva has a one year low of $4.75 and a one year high of $12.25. The stock has a market cap of $676.57 million, a PE ratio of -3.38 and a beta of 1.77. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14. The stock has a 50 day moving average price of $5.24 and a 200 day moving average price of $6.92.

Key Headlines Impacting Valneva

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s marketing authorization application for their six-valent Lyme disease vaccine candidate, PF-07307405. The validation allows the EMA to begin its formal assessment, a significant step toward potential approval and commercialization. The vaccine is being developed in partnership with Pfizer, with regulatory decisions potentially targeted within the next year. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: Investor attention is increasing around the potential Lyme vaccine market. Reports said the European Union will study the candidate, which could address an unmet need as Lyme disease cases rise and no broadly available human vaccine is currently marketed. EU to study potential vaccine for Lyme disease: companies
• Neutral Sentiment: TD Cowen initiated research coverage on Valneva. New analyst coverage may improve visibility, but the article did not provide a rating or price target that would establish a clear trading signal. Valneva Research Coverage Started at TD Cowen
• Negative Sentiment: Valneva’s second-quarter earnings missed expectations: the company reported a loss of $0.40 per share versus a consensus loss of $0.23, while revenue of $39.37 million fell short of the $43.15 million estimate. The company continues to report substantial losses, reflected in its negative net margin and return on equity. Valneva Earnings Results
• Neutral Sentiment: Management reaffirmed its 2026 financial outlook while emphasizing a strategic focus on commercial execution and the Lyme vaccine program. The guidance provides some visibility, but profitability and the timing of potential Lyme vaccine revenue remain uncertain. Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on VALN. The Goldman Sachs Group lowered shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target for the company. in a research report on Wednesday, April 22nd. Wall Street Zen raised shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. TD Cowen started coverage on Valneva in a research report on Tuesday. They set a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Valneva presently has a consensus rating of “Hold” and an average price target of $11.98.

Institutional Trading of Valneva

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Marex Group plc acquired a new position in Valneva in the second quarter valued at approximately $64,000. JPMorgan Chase & Co. acquired a new stake in shares of Valneva during the 3rd quarter worth about $124,000. Finally, XTX Topco Ltd purchased a new stake in Valneva in the 4th quarter valued at about $94,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.